Skip to main content

Advertisement

SpringerLink
Log in

Methodological quality evaluation of systematic reviews or meta-analyses on ERCC1 in non-small cell lung cancer: a systematic review

  • Review – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purposes

To assess the methodological quality of systematic reviews (SRs) or meta-analysis concerning the predictive value of ERCC1 in platinum chemotherapy of non-small cell lung cancer.

Methods

We searched the PubMed, EMbase, Cochrane library, international prospective register of systematic reviews, Chinese BioMedical Literature Database, China National Knowledge Infrastructure, Wan Fang and VIP database for SRs or meta-analysis. The methodological quality of included literatures was evaluated by risk of bias in systematic review (ROBIS) scale.

Results

Nineteen eligible SRs/meta-analysis were included. The most frequently searched databases were EMbase (74%), PubMed, Medline and CNKI. Fifteen SRs did additional retrieval manually, but none of them retrieved the registration platform. 47% described the two-reviewers model in the screening for eligible original articles, and seven SRs described the two reviewers to extract data. In methodological quality assessment, inter-rater reliability Kappa was 0.87 between two reviewers. Research question were well related to all SRs in phase 1 and the eligibility criteria was suitable for each SR, and rated as ‘low’ risk bias. But the ‘high’ risk bias existed in all the SRs regarding methods used to identify and/or select studies, and data collection and study appraisal. More than two-third of SRs or meta-analysis were finished with high risk of bias in the synthesis, findings and the final phase.

Conclusions

The study demonstrated poor methodological quality of SRs/meta-analysis assessing the predictive value of ERCC1 in chemotherapy among the NSCLC patients, especially the high performance bias. Registration or publishing the protocol is recommended in future research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N (2007) ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2(10):902–906

    Article  PubMed  Google Scholar 

  • Buhn S, Mathes T, Prengel P et al (2017) The risk of bias in systematic reviews (ROBIS) tool showed fair reliability and good construct validity. J Clin Epidemiol. doi:10.1016/j.jclinepi.2017.06.019

    PubMed  Google Scholar 

  • Cecere F, Bria E, Rosell R (2006) DNA repair by ERCC1 in non-small-cell lung cancer. N Engl J Med 355(24):2590–2591 (Author reply 1)

    Article  PubMed  Google Scholar 

  • Chen S, Zhang J, Wang R, Luo X, Chen H (2010) The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 70(1):63–70. doi:10.1016/j.lungcan.2010.05.010 (Epub Jun 11)

    Article  PubMed  Google Scholar 

  • Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132

    Article  PubMed  Google Scholar 

  • De Angelis C, Drazen JM, Frizelle FA et al (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. CMAJ 171(6):606–607

    Article  PubMed  PubMed Central  Google Scholar 

  • Fenghua X, Rongrong G, Xin L, Liyan L, Zhang G (2013) Relationship between ERCC1 expression and sensitivity of platinum-based chemotherapy in NSCLC: a systematic review. Chin J Clin Pharmacol Ther 18(1):45–50

    Google Scholar 

  • Ghoussaini M, Fletcher O, Michailidou K et al (2012) Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 44(3):312–318

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Han Y, Liu J, Sun M, Zhang Z, Liu C, Sun Y (2016) A significant statistical advancement on the predictive values of ERCC1 polymorphisms for clinical outcomes of platinum-based chemotherapy in non-small cell lung cancer: an updated meta-analysis. Dis Mark 2016:7643981. doi:10.1155/2016/7643981 (Epub 2016 Jan 21)

    Google Scholar 

  • Hubner RA, Riley RD, Billingham LJ, Popat S (2011) Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS One 6(10):e25164. doi:10.1371/journal.pone.0025164 (Epub 2011 Oct 14)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jameson JL, Longo DL (2015) Precision medicine—personalized, problematic, and promising. N Engl J Med 372(23):2229–2234

    Article  CAS  PubMed  Google Scholar 

  • Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q (2012) ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep 39(6):6933–6942. doi:10.1007/s11033-012-1520-4

    Article  CAS  PubMed  Google Scholar 

  • Jiang LI, Kai SU, Yao HUANG et al (2016) Lung cancer screening: an overview of systematic reviews. Chin J Evid-based Med 16(7):764–770

    Google Scholar 

  • Levine DM, Ek WE, Zhang R et al (2013) A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett’s esophagus. Nat Genet 45(12):1487–1493

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li Z, Qing Y, Guan W et al (2014) Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum–paclitaxel chemotherapy. Cancer Chemother Pharmacol 74(4):777–786. doi:10.1007/s00280-014-2562-1 (Epub 2014 Aug 9)

    Article  CAS  PubMed  Google Scholar 

  • Li F, Xie X, Ren X, Zhang J (2016) A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy. Cancer Chemother Pharmacol 77(6):1183–1191

    Article  CAS  PubMed  Google Scholar 

  • Michailidou K, Beesley J, Lindstrom S et al (2015) Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet 47(4):373–380

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • NSCLC Meta-analyses Collaborative Group (2010) Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375(9722):1267–1277

    Article  PubMed Central  Google Scholar 

  • Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983–991

    Article  CAS  PubMed  Google Scholar 

  • Ozdemir O, Ozdemir P, Veral A, Uluer H, Ozhan MH (2013) ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy. Asian Pac J Cancer Prev 14(8):4679–4683

    Article  PubMed  Google Scholar 

  • Paliogiannis P, Attene F, Cossu A et al (2013) Lung cancer epidemiology in North Sardinia, Italy. Multidiscip Respir Med 8(1):45

    Article  PubMed  PubMed Central  Google Scholar 

  • Pignon J, Tribodet H, Scagliotti G (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26(210):3552–3559

    Article  PubMed  Google Scholar 

  • Qian J, Gang J, Wang Y (2012) Meta-analysis of correlation between ERCC1 expression and efficacy of platinum-based chemotherapy in non-small lung cancer patients. Chin J Cancer Prev Treat 19(2):123–126

    Google Scholar 

  • Roth JA, Carlson JJ (2011) Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer 12(6):393–401. doi:10.1016/j.cllc.2011.04.005 (Epub Jul 1)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Song Yong, Ying Wu, Shen P (2009) A meta-analysis of ERCC1 SNP and chemosensitivity to cisplatin in patients with advanced non-small cell lung cancer. J Evid-Based Med 4(2):98–100

    Google Scholar 

  • The International Adjuvant Lung Cancer Trial Collaborative Group (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non–small-cell lung cancer. N Engl J Med 350(4):351–360

    Article  Google Scholar 

  • Wei S, Shi Y, Yong S (2010) Meta-analysis of predictive value of ERCC1 protein expression in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Evid-Based Med 6:20

    Google Scholar 

  • Wei SZ, Zhan P, Shi MQ et al (2011a) Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol 28(1):315–321. doi:10.1007/s12032-010-9443-1 (Epub 2010 Feb 9)

    Article  CAS  PubMed  Google Scholar 

  • Wei HB, Lu XS, Shang LH et al (2011b) Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Arch Med Res 42(5):412–420. doi:10.1016/j.arcmed.2011.07.008 (Epub Aug 7)

    CAS  PubMed  Google Scholar 

  • Wei HB, Hu J, Shang LH et al (2012) A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer. Chin Med J (Engl) 125(16):2902–2907

    CAS  Google Scholar 

  • Wellcome Trust Case Control C (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447(7145):661–678

    Article  Google Scholar 

  • Whiting P, Savovic J, Higgins JP et al (2016) ROBIS: a new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol 69:225–234

    Article  PubMed  PubMed Central  Google Scholar 

  • Wilcox JE (2006) DNA repair by ERCC1 in non-small-cell lung cancer. N Engl J Med 355(24):2590 (Author reply 1)

    Article  CAS  PubMed  Google Scholar 

  • Wu C, Hu Z, He Z et al (2011) Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat Genet 43(7):679–684

    Article  CAS  PubMed  Google Scholar 

  • Wu C, Wang Z, Song X et al (2014) Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. Nat Genet 46(9):1001–1006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xu TP, Shen H, Liu LX, Shu YQ (2013) Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Gene 526(2):265–274. doi:10.1016/j.gene.2013.05.021 (Epub May 30)

    Article  CAS  PubMed  Google Scholar 

  • Yang Y, Xian L (2014) The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol 35(4):2905–2921. doi:10.1007/s13277-013-1493-5 (Epub 2013 Dec 13)

    Article  CAS  PubMed  Google Scholar 

  • Yang Y, Luo X, Yang N, Feng R, Xian L (2014) The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis. PLoS One 9(11):e111651

    Article  PubMed  PubMed Central  Google Scholar 

  • Yin M, Yan J, Voutsina A et al (2011) No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer 72(3):370–377. doi:10.1016/j.lungcan.2010.10.011 (Epub Nov 13)

    Article  PubMed  Google Scholar 

  • Yu D, Shi J, Sun T et al (2012) Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients. Tumour Biol 33(3):877–884. doi:10.1007/s13277-011-0314-y (Epub 2012 Jan 17)

    Article  CAS  PubMed  Google Scholar 

  • Yu SN, Liu GF, Li XF, Fu BH, Dong LX, Zhang SH (2017) Evaluation of prediction of polymorphisms of DNA repair genes on the efficacy of platinum-based chemotherapy in patients with non-small cell lung cancer: a network meta-analysis. J Cell Biochem. doi:10.1002/jcb.26147

    Google Scholar 

Download references

Acknowledgements

We greatly appreciate the support from other members of the study team who provided their generous contribution of time and efforts help during the study.

Author information

Authors and Affiliations

  1. Department of Evidence-based Medicine and Clinical Epidemiology, West China Medical School of Medicine/West China Hospital, Sichuan University, 37 Guo Xue Xiang, Cheng Du, 610041, China

    Huan Tao, Qian Li & Jin Chen

  2. Department of Respiratory Medicine of the First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, 22 Shuangyong street, Nanning, 530021, China

    Yueyuan Zhang

Authors
  1. Huan Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yueyuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qian Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jin Chen.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

This study was not funded by any funding agencies in the public, commercial, or not-for-profit sectors.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors. All the data involved in this study were extracted from published articles.

Informed consent

Informed consent was not involved since all the data in this study were extracted from published articles.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (RAR 94 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tao, H., Zhang, Y., Li, Q. et al. Methodological quality evaluation of systematic reviews or meta-analyses on ERCC1 in non-small cell lung cancer: a systematic review. J Cancer Res Clin Oncol 143, 2245–2256 (2017). https://doi.org/10.1007/s00432-017-2516-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-017-2516-1

Keywords

Search

Navigation